Which peptides have evidence for weight loss?
The strongest evidence belongs to approved incretin-based prescription medicines, not to products marketed generically as “fat-burning peptides.” Semaglutide is a GLP-1 receptor agonist. Tirzepatide activates both GIP and GLP-1 receptors. In large randomized trials, specific branded formulations produced clinically meaningful average weight loss alongside lifestyle intervention, leading to regulatory approvals for chronic weight management in defined populations.
That does not make every product labeled semaglutide or tirzepatide an approved medicine, and it does not make investigational compounds approved alternatives. Benefits, risks, contraindications, manufacturing controls, and follow-up are part of prescription treatment. This article maps the evidence and status without giving dosing or personal-use instructions.
- Semaglutide
- GLP-1 agonist Approved prescription formulations include chronic weight management
- Tirzepatide
- GIP/GLP-1 agonist A dual agonist, not simply a GLP-1 drug
- Next generation
- Still investigational Retatrutide and survodutide are not approved medicines
How incretin medicines change appetite and metabolism
GLP-1 signaling can increase glucose-dependent insulin secretion, reduce inappropriate glucagon signaling, slow gastric emptying, and influence appetite centers. GIP signaling adds another nutrient-responsive pathway. In weight-management trials, reduced energy intake appears to be a major driver; describing these medicines as direct “fat burners” misses how they work.
Glucagon-receptor activity is being studied in newer multi-agonists because it may influence energy expenditure and liver metabolism, but it can also create physiological trade-offs. Receptor activity alone cannot predict net weight loss or safety. Those questions require controlled clinical trials with adequate duration and diverse participants.
- 01Receptor activationGLP-1, GIP, or glucagon pathways respond
- 02Physiology changesAppetite, glucose handling, and gastric emptying may shift
- 03Behavioral effectAverage energy intake may fall over time
- 04Trial outcomeWeight, health markers, adverse events, and discontinuation are measured
Semaglutide and tirzepatide: approved but different
Semaglutide is used in different prescription products for different indications, including type 2 diabetes and chronic weight management. The evidence and authorization belong to the particular product, formulation, population, and label. Its obesity trials also include outcomes beyond the scale, and one approved formulation has cardiovascular risk-reduction labeling for certain adults with cardiovascular disease and overweight or obesity.
Tirzepatide is a single molecule with GIP- and GLP-1-receptor agonism. Specific products are approved for type 2 diabetes and chronic weight management, and the weight-management product also has an obstructive sleep apnea indication for certain adults with obesity. Calling tirzepatide “a GLP-1 peptide” is incomplete because its dual pharmacology is central to its classification.
These medicines can cause gastrointestinal adverse effects and have important warnings, precautions, and contraindications. Weight regain after treatment discontinuation has occurred in trials, which reinforces that obesity is a chronic disease rather than a short “cycle.” Individual treatment decisions require licensed clinical care.
Retatrutide and survodutide: investigational multi-agonists
Retatrutide is an investigational triple agonist that activates GIP, GLP-1, and glucagon receptors. As of this guide’s August 2026 review, phase 3 trials have reported positive results, but retatrutide remains investigational and is not FDA-approved. Topline results are important, yet full peer-reviewed analyses, the complete development program, and regulatory review still matter.
Survodutide is not a triple agonist. It is an investigational dual glucagon/GLP-1 receptor agonist in phase 3 development for obesity and related metabolic conditions. It should not be grouped with retatrutide as though the two molecules have identical targets, trial results, or safety profiles.
| Compound | Receptor classification | Status as reviewed August 2026 |
|---|---|---|
| Semaglutide | GLP-1 receptor agonist | Approved prescription products for specific indications, including weight management |
| Tirzepatide | GIP/GLP-1 dual receptor agonist | Approved prescription products for specific indications, including weight management |
| Retatrutide | GIP/GLP-1/glucagon triple receptor agonist | Investigational; phase 3 program, not FDA-approved |
| Survodutide | Glucagon/GLP-1 dual receptor agonist | Investigational; phase 3 program, not FDA-approved |
AOD9604 and hGH fragment 176–191 claims
AOD9604 is a synthetic, modified peptide based on the C-terminal region of human growth hormone. More precisely, it contains hGH residues 177–191 plus an added N-terminal tyrosine; it is not full-length growth hormone. It was designed to investigate metabolic effects without activating the classic growth hormone/IGF-1 growth pathway.
Early studies and animal models generated interest, but the larger 24-week phase 2b obesity trial did not show statistically significant weight loss versus placebo, and the obesity drug program was discontinued. Claims that AOD9604 suppresses appetite, accelerates recovery, preserves muscle, or produces reliable human fat loss go beyond the clinical evidence. It is not an FDA-approved weight-loss medicine.
“hGH fragment 176–191” is commonly used as a marketing label for a related research sequence, but it should not be treated as synonymous with clinically proven AOD9604 or with human growth hormone. Most fat-loss claims for the fragment trace to mechanistic or animal work rather than robust obesity trials. Full-length recombinant human growth hormone has approved medical uses for diagnosed conditions; it is not approved as a general weight-loss treatment.
- Semaglutide and tirzepatideestablished
Large randomized programs support approved prescription indications, with ongoing safety monitoring.
- RetatrutidePhase 3, investigational
Positive pivotal results do not equal regulatory approval or general availability as a medicine.
- SurvodutidePhase 3, investigational
Human efficacy and safety are under active study for its dual-receptor mechanism.
- AOD9604mixed
Early signals were not confirmed in the pivotal obesity study; it is not an approved weight-loss drug.
- hGH fragment 176–191preclinical
Mechanistic and animal claims outweigh controlled human weight-loss evidence.
Frequently asked questions about weight-loss peptides
- 01IdentityWhich exact molecule?
Similar marketing names can hide different sequences, salts, formulations, or receptor targets.
- 02EvidenceWhich trial phase?
Animal data, early human studies, phase 3 results, and approval are distinct milestones.
- 03OutcomeWhat was measured?
Body weight, fat mass, glucose, cardiovascular outcomes, and tolerability answer different questions.
Are retatrutide and survodutide available prescription medicines?
No. Both remain investigational as of August 2026. Participation in a regulated clinical trial is different from encountering a product advertised online with an investigational compound’s name.
Is tirzepatide a GLP-1 agonist?
It activates the GLP-1 receptor, but its complete classification is a dual GIP/GLP-1 receptor agonist. Semaglutide is a single GLP-1 receptor agonist.
Does “fat-burning peptide” describe a medical category?
No. It is a marketing phrase that can group together approved medicines, failed drug candidates, and preclinical compounds. Exact identity, indication, study quality, and regulatory status are more informative.